Article

A DRD4/BDNF gene-gene interaction associated with maximum BMI in women with bulimia nervosa

Eating Disorders Program, Toronto General Hospital, Toronto, Canada.
International Journal of Eating Disorders (Impact Factor: 3.03). 01/2008; 41(1):22-8. DOI: 10.1002/eat.20474
Source: PubMed

ABSTRACT The goals of the current study were threefold: 1) to examine whether the hypofunctional 7R allele of the DRD4 gene contributes to maximal lifetime body mass in women with BN; 2) to determine whether the BDNF gene contributes to maximal BMI on its own, and 3) to explore possible BDNF/DRD4 gene-gene interactions in mediating maximum lifetime BMIs in BN.
We tested two General Linear Models predicting maximum lifetime BMI with the exon 3 VNTR polymorphism of the dopamine-4 receptor gene (DRD4) and either the Val66Met or the -270C/T polymorphism of BDNF respectively in 163 female probands with BN, purging subtype.
In these bulimic subjects, the hypofunctional 7R allele of DRD4 predicted maximal BMI (p < .01). There was also a significant interaction between the DRD4 gene and the BDNF gene in predicting maximal BMI. The Val66Met rather than the 270C/T polymorphism of BDNF interacting with DRD4 predicted maximum BMI in this BN sample (p < .01). Probands carrying both the hypofunctional 7R allele of DRD4 and the Met66 allele of BDNF had significantly higher maximal BMI than did probands in the other gene-gene interaction groups.
These results provide further evidence that the hypofunctional 7R allele of DRD4 contributes to weight gain in women with BN and that the BDNF gene interacts with DRD4 to influence weight regulation in these subjects.

1 Follower
 · 
92 Views
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eating disorders, like anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorders (BED), are described as abnormal eating habits that usually involve insufficient or excessive food intake. Animal models have been developed that provide insight into certain aspects of eating disorders. Several drugs have been found efficacious in these animal models and some of them have eventually proven useful in the treatment of eating disorders. This review will cover the role of monoaminergic neurotransmitters in eating disorders and their pharmacological manipulations in animal models and humans. Dopamine, serotonin (5-HT) and noradrenaline in hypothalamic and striatal regions regulate food intake by affecting hunger and satiety and by affecting rewarding and motivational aspects of feeding. Reduced dopaminergic, 5-HTergic and noradrenergic neurotransmission and compensatory changes, at least in dopamine 2-type and 5-HT2C/2A receptors, have been related to pathophysiology of AN in humans and animal models. Also, in disorders and animal models of BN and BED monoaminergic neurotransmission is downregulated, but receptor level changes are different from those seen in AN. A hypofunctional dopamine system or overactive α2-adrenoceptors may contribute to an attenuated response to (palatable) food and result in hedonic binge eating. Evidence for the efficacy of monoaminergic treatments for AN is limited, while more support exists for the treatment of BN or BED with monoaminergic drugs.
    British Journal of Pharmacology 05/2014; 171(20). DOI:10.1111/bph.12789 · 4.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eating disorders are characterized by severe distortions of food intake in people who have altered eating patterns, secondary to psychological derangement. This group of diseases involve several entities which vary greatly and are classified as: anorexia nervosa, bulimia nervosa, "eating disorder not otherwise specified" and binge eating disorder. All of them are more common in women and generally begin during adolescence, becoming chronic diseases. The precise etiology has not been elucidated but different theories have been proposed to explain it. The main problem regarding eating disorders, thus, these patients are managed in interdisciplinary groups offering: psychotherapy, support strategies during the psychotherapeutic process and a psycho-educational program. The whole process takes from months to several years. Professional staff includes psychologists, psychiatrists, internists, endocrinologists and nutritionists.
    12/2008; 65(6):579-592.